Merck Millipore paper calls on emerging companies to drive drug discovery

Merck Millipore has published an original white paper recognising the impact the emerging biotech community can have on the future of drug development.

Based on discussions during the company's Emerging Biotech executive summit on June 15th in Philadelphia, the paper examines strategies to advance promising molecules and bring lifesaving drugs to market faster.

The purpose of the white paper is to encourage and continue open dialogue around investments, partnerships and building value in drug development, building upon the panel discussions that were initiated at the summit.

Udit Batra, president and chief executive officer of Merck Millipore, said: "Emerging biotech companies are a critical component and source of innovation, helping to bring groundbreaking drug products to market."

A total of 40 biotech leaders from across the US came together at the June summit, representing more than one hundred molecules.

Their insights have been included in the paper, encompassing discussions of limited capabilities, expertise and funding, and insight on how to overcome these hurdles.